NRx Pharma Treats Patients

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered, sub-millimetric image guidance is now being applied in HOPE's outpatient TMS workflows for patients with Major Depressive Disorder and other CNS conditions Milestone advances HOPE's interventional psychiatry platform and aligns with NRx's planned trial of NRX-101 in combination with robotic-enabled TMS in civilian and military treatment facilities (the SPARC-TMS trial).

WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP ) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System.

HOPE has installed Zeta TMS Navigation Systems at its clinics in West Palm Beach and Sarasota, Florida, with Zeta-navigated patient treatments now underway at both locations.

The first treatments mark HOPE's transition from system deployment to active patient care, bringing AI-powered, sub-millimetric image guidance into routine outpatient TMS workflows for patients with Major Depressive Disorder and other neurological conditions.

The Zeta TMS Navigation System uses proprietary RealTrack™ technology to provide real-time, markerless image guidance for TMS procedures, applying artificial intelligence and computer vision to register a patient's MRI or CT imaging to their facial anatomy in under two minutes and to continuously track the position of the TMS coil relative to the planned brain target with sub-millimetric accuracy.